SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Elder Pharmaceuticals trades higher on the bourses

12 Mar 2015 Evaluate

Elder Pharmaceuticals is currently trading at Rs. 113.00, up by 0.60 points or 0.53 % from its previous closing of Rs. 112.40 on the BSE.

The scrip opened at Rs. 112.50 and has touched a high and low of Rs. 117.00 and Rs. 111.00 respectively. So far 9868 shares were traded on the counter.

The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 257.00 on 10-Apr-2014 and a 52 week low of Rs. 102.65 on 30-Dec-2014.

Last one week high and low of the scrip stood at Rs. 115.00 and Rs. 107.10 respectively. The current market cap of the company is Rs. 232.07 crore.

The promoters holding in the company stood at 27.67 % while Institutions and Non-Institutions held 25.61 % and 46.72 % respectively.

Elder Pharmaceuticals has made major pending statutory payments of TDS, Provident Fund, ESIC, Maharashtra Labour Welfare Fund (MLWF) etc to the tune of roughly Rs 26 crore. The company which was going through erratic cash flow situation since some time plans to clear the backlog of other payments very soon. The company is also in talks to raise fresh funds through a combination of debt and equity.

Elder Pharmaceuticals has around six manufacturing units in India, all as per international standards. Post increasing its stake in Elder Biomeda AD and Neutrahealth PLC, EPL also has access to the manufacturing units of these companies in Bulgaria and Birmingham, UK respectively coupled with distribution network and brands of the same.

Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×